Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension Period

NCT05598320 is registered in ClinicalTrials.gov with Ascendis Pharma Growth Disorders A/S as lead sponsor.

NCT NCT05598320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05598320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension Period
Lead sponsor
Ascendis Pharma Growth Disorders A/S
Phase
Phase 2/3
Overall status
Completed
Start date
March 3, 2023
Completion date
August 13, 2025
Enrollment
84 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

achondroplasia